|
|
Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins. Pharmacogenomics. 2012. Khrunin Andrey, et al. [Article:22188361@PubMed] |
|
|
Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration. The pharmacogenomics journal. 2012. Fernandez-Rozadilla C, et al. [Article:22310351@PubMed] |
|
|
Polymorphisms of GSTP1 is associated with differences of chemotherapy response and toxicity in breast cancer. Chinese medical journal. 2011. Zhang Bai-Lin, et al. [Article:21362365@PubMed] |
|
|
Pharmacogenetics of Oxaliplatin as Adjuvant Treatment in Colon Carcinoma: Are Single Nucleotide Polymorphisms in GSTP1, ERCC1, and ERCC2 Good Predictive Markers?. Molecular diagnosis & therapy. 2011. Fariña Sarasqueta Arantza, et al. [Article:21958378@PubMed] |
|
|
Genotoxic effects of doxorubicin in cultured human lymphocytes with different glutathione S-transferase genotypes. Mutation research. 2011. Ramos D L, et al. [Article:21640195@PubMed] |
|
|
Pharmacogenomics of cisplatin-induced ototoxicity. Pharmacogenomics. 2011. Mukherjea Debashree, et al. [Article:21787192@PubMed] |
|
|
Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer. Pharmacogenomics. 2011. Lamas Maria J, et al. [Article:21449681@PubMed] |
|
|
Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. Breast cancer research : BCR. 2010. Gor Priya P, et al. [Article:20459744@PubMed] |
|
|
Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis. British journal of cancer. 2010. Zarate R, et al. [Article:20216541@PubMed] |
|
|
Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. British journal of clinical pharmacology. 2010. Etienne-Grimaldi Marie-Christine, et al. [Article:20078613@PubMed] |
|
|
Glutathione pathway genetic polymorphisms and lung cancer survival after platinum-based chemotherapy. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2010. Moyer Ann M, et al. [Article:20200426@PubMed] |
|
|
Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors. Fertility and sterility. 2010. Su H Irene, et al. [Article:19376514@PubMed] |
|
|
GSTT1, GSTM1, and GSTP1 polymorphisms and chemotherapy response in locally advanced breast cancer. Genetics and molecular research : GMR. 2010. Oliveira A L, et al. [Article:20568049@PubMed] |
|
|
Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010. Boige Valérie, et al. [Article:20385995@PubMed] |
|
|
Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010. McLeod Howard L, et al. [Article:20530282@PubMed] |
|
|
Association of genetic polymorphisms with hepatotoxicity in patients with childhood acute lymphoblastic leukemia or lymphoma. Pediatric hematology and oncology. 2010. Horinouchi Masanori, et al. [Article:20670164@PubMed] |
|
|
The GSTP1 Ile105 Val polymorphism modifies the metabolism of toluene di-isocyanate. Pharmacogenetics and genomics. 2010. Broberg Karin E, et al. [Article:20032816@PubMed] |
|
|
Genetic polymorphisms in GST genes and survival of colorectal cancer patients treated with chemotherapy. Pharmacogenomics. 2010. Funke Silvia, et al. [Article:20017670@PubMed] |
|
|
Pharmacogenetics in reproductive and perinatal medicine. Pharmacogenomics. 2010. Alfirevic Ana, et al. [Article:20017673@PubMed] |
|
|
Rescue of paclitaxel sensitivity by repression of Prohibitin1 in drug-resistant cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 2010. Patel Nish, et al. [Article:20133800@PubMed] |
|
|
A large-scale candidate gene approach identifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiation in rectal cancer. The pharmacogenomics journal. 2010. Ho-Pun-Cheung A, et al. [Article:20644561@PubMed] |
|
|
Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. The pharmacogenomics journal. 2010. Khrunin A V, et al. [Article:19786980@PubMed] |
|
|
SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance. The pharmacogenomics journal. 2010. Edvardsen H, et al. [Article:20157331@PubMed] |
|
|
Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy. The pharmacogenomics journal. 2010. Cecchin E, et al. [Article:20368715@PubMed] |
|
|
Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics. Transactions of the American Clinical and Climatological Association. 2010. Goldberg Richard M, et al. [Article:20697547@PubMed] |
|
|
Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC). BMC cancer. 2009. Glaysher Sharon, et al. [Article:19712441@PubMed] |
|
|
Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa. British journal of clinical pharmacology. 2009. Ekhart Corine, et al. [Article:19076156@PubMed] |
|
|
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009. Voso Maria Teresa, et al. [Article:19638460@PubMed] |
|
|
Chronic obstructive pulmonary disease: towards pharmacogenetics. Genome medicine. 2009. Wood Alice M, et al. [Article:19951401@PubMed] |
|
|
Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecologic oncology. 2009. Kim Hee Seung, et al. [Article:19203783@PubMed] |
|
|
Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009. Goekkurt Eray, et al. [Article:19332728@PubMed] |
|
|
Meta-analysis study of glutathione-S-transferases (GSTM1, GSTP1, and GSTT1) gene polymorphisms and risk of acute myeloid leukemia. Leukemia & lymphoma. 2009. Das Prabhavathy, et al. [Article:19811334@PubMed] |
|
|
Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2009. Rocha V, et al. [Article:19005482@PubMed] |
|
|
Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nature genetics. 2009. Ross Colin J D, et al. [Article:19898482@PubMed] |
|
|
Gene single nucleotide polymorphism accumulation improves survival in advanced head and neck cancer patients treated with weekly paclitaxel. The Laryngoscope. 2009. Grau Juan J, et al. [Article:19504558@PubMed] |
|
|
Pharmacogenetics and biomarkers in colorectal cancer. The pharmacogenomics journal. 2009. Strimpakos A S, et al. [Article:19381163@PubMed] |
|
|
ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study. BMC cancer. 2008. Huang Ming-Yii, et al. [Article:18267032@PubMed] |
|
|
Glutathione s-transferase p1: gene sequence variation and functional genomic studies. Cancer research. 2008. Moyer Ann M, et al. [Article:18559526@PubMed] |
|
|
Population pharmacokinetics of melphalan and glutathione S-transferase polymorphisms in relation to side effects. Clinical pharmacology and therapeutics. 2008. Kühne A, et al. [Article:17914442@PubMed] |
|
|
Glutathione S-transferase P1 Ile105Val polymorphism is associated with haematological toxicity in elderly rectal cancer patients receiving preoperative chemoradiotherapy. Drugs & aging. 2008. Agostini Marco, et al. [Article:18540691@PubMed] |
|
|
Association between GSTP1 gene polymorphism and serum alpha-GST concentrations undergoing sevoflurane anaesthesia. European journal of anaesthesiology. 2008. Kaymak C, et al. [Article:17892615@PubMed] |
|
|
Pathway based analysis of SNPs with relevance to 5-FU therapy: relation to intratumoral mRNA expression and survival. International journal of cancer. Journal international du cancer. 2008. Nordgard Silje H, et al. [Article:18498133@PubMed] |
|
|
Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Molecular cancer therapeutics. 2008. Peklak-Scott Christina, et al. [Article:18852128@PubMed] |
|
|
Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenetics and genomics. 2008. Ekhart Corine, et al. [Article:18496131@PubMed] |
|
|
Pharmacogenetics in colorectal cancer: a systematic review. Pharmacogenomics. 2008. Funke Silvia, et al. [Article:18681783@PubMed] |
|
|
Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood. 2007. Kishi Shinji, et al. [Article:17264302@PubMed] |
|
|
Association of A313 G polymorphism (GSTP1*B) in the glutathione-S-transferase P1 gene with sporadic Parkinson's disease. European journal of neurology : the official journal of the European Federation of Neurological Societies. 2007. Vilar R, et al. [Article:17250723@PubMed] |
|
|
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007. Ruzzo Annamaria, et al. [Article:17401013@PubMed] |
|
|
Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. Journal of human genetics. 2007. Imanishi Hiroyuki, et al. [Article:17180579@PubMed] |
|
|
Genetic polymorphisms and benzene metabolism in humans exposed to a wide range of air concentrations. Pharmacogenetics and genomics. 2007. Kim Sungkyoon, et al. [Article:17885617@PubMed] |
|
|
Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome. Pharmacogenomics. 2007. Le Morvan Valérie, et al. [Article:18085999@PubMed] |
|
|
Glutathione S-transferases pi 1, alpha 1 and M3 genetic polymorphisms and the risk of hepatocellular carcinoma in humans. Pharmacogenomics. 2007. Ladero José M, et al. [Article:17716224@PubMed] |
|
|
Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)--novel predictors for response and survival in gastric cancer patients. British journal of cancer. 2006. Goekkurt E, et al. [Article:16317430@PubMed] |
|
|
Estrogens, enzyme variants, and breast cancer: a risk model. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2006. Crooke Philip S, et al. [Article:16985022@PubMed] |
|
|
Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006. Lecomte Thierry, et al. [Article:16707601@PubMed] |
|
|
Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006. Yang Ping, et al. [Article:16603718@PubMed] |
|
|
Influence of glutathione-S-transferase (GSTM1, GSTP1, GSTT1) and cytochrome p450 (CYP1A1, CYP2D6) polymorphisms on numbers of basal cell carcinomas (BCCs) in families with the naevoid basal cell carcinoma syndrome. Journal of medical genetics. 2006. R Yang X, et al. [Article:16582078@PubMed] |
|
|
A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2006. Pillot Giancarlo A, et al. [Article:17409981@PubMed] |
|
|
Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2006. Booton Richard, et al. [Article:17409936@PubMed] |
|
|
Relationships between genetic polymorphisms and anticancer drug cytotoxicity vis-à-vis the NCI-60 panel. Pharmacogenomics. 2006. Le Morvan Valérie, et al. [Article:16981845@PubMed] |
|
|
Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood. 2005. Rocha Jose Claudio C, et al. [Article:15713801@PubMed] |
|
|
Polymorphism discovery in 51 chemotherapy pathway genes. Human molecular genetics. 2005. Freimuth Robert R, et al. [Article:16239245@PubMed] |
|
|
A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. British journal of cancer. 2004. Stoehlmacher J, et al. [Article:15213713@PubMed] |
|
|
Phase 1 study of TLK286 (Telcyta) administered weekly in advanced malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004. Rosen Lee S, et al. [Article:15173075@PubMed] |
|
|
Glutathione S-transferase M1 polymorphism and the risk of lung cancer. Anticancer research. 2003. Mohr Lawrence C, et al. [Article:12894585@PubMed] |
|
|
Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma. Blood. 2003. Dasgupta Ranjit K, et al. [Article:12791655@PubMed] |
|
|
Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. Journal of the National Cancer Institute. 2002. Stoehlmacher Jan, et al. [Article:12072547@PubMed] |
|
|
Effects of the ADH3, CYP2E1, and GSTP1 genetic polymorphisms on their expressions in Caucasian lung tissue. Lung cancer (Amsterdam, Netherlands). 2002. Yang Mihi, et al. [Article:12367788@PubMed] |
|
|
Efficacy of a glutathione S-transferase pi-activated prodrug in platinum-resistant ovarian cancer cells. Molecular cancer therapeutics. 2002. Townsend Danyelle M, et al. [Article:12481432@PubMed] |
|
|
Tobacco smoke reduces viability in human lung fibroblasts: protective effect of glutathione S-transferase P1. American journal of physiology. Lung cellular and molecular physiology. 2001. Ishii T, et al. [Article:11350797@PubMed] |
|
|
Role of glutathione S-transferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance. International journal of cancer. Journal international du cancer. 2001. Harbottle A, et al. [Article:11351295@PubMed] |
|
|
Glutathione-S-transferase family of enzymes. Mutation research. 2001. Strange R C, et al. [Article:11535245@PubMed] |
|
|
Doxorubicin- and daunorubicin-glutathione conjugates, but not unconjugated drugs, competitively inhibit leukotriene C4 transport mediated by MRP/GS-X pump. Biochemical and biophysical research communications. 1998. Priebe W, et al. [Article:9647783@PubMed] |
|
|
Coordinated action of glutathione S-transferases (GSTs) and multidrug resistance protein 1 (MRP1) in antineoplastic drug detoxification. Mechanism of GST A1-1- and MRP1-associated resistance to chlorambucil in MCF7 breast carcinoma cells. The Journal of biological chemistry. 1998. Morrow C S, et al. [Article:9685354@PubMed] |
|
|
An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. Cancer research. 1997. Lavigne J A, et al. [Article:9407957@PubMed] |
|
|
Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins. The Journal of biological chemistry. 1997. Ali-Osman F, et al. [Article:9092542@PubMed] |
|
|
Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug metabolism and disposition: the biological fate of chemicals. 1996. Czerwinski M, et al. [Article:8886613@PubMed] |
|
|
Glutathione and related enzymes in multidrug resistance. European journal of cancer (Oxford, England : 1990). 1996. O'Brien M L, et al. [Article:8763337@PubMed] |
|
|
Glutathione conjugation of the cytostatic drug ifosfamide and the role of human glutathione S-transferases. Chemical research in toxicology. 1995. Dirven H A, et al. [Article:8555414@PubMed] |
|
|
The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Critical reviews in biochemistry and molecular biology. 1995. Hayes J D, et al. [Article:8770536@PubMed] |
|
|
Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Cancer research. 1994. Dirven H A, et al. [Article:7954469@PubMed] |